ADTX Aditxt, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ADTX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$0.51
52W High
$2542.5
52W Low
$0.5
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
95%
Analysis Accuracy
ADTX exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and the absence of an Altman Z-Score, which raises bankruptcy risk concerns. The company is unprofitable with a negative ROA of -61.70%, a gross margin of 0.00%, and a staggering -419,870.30% operating margin. Revenue has collapsed by 89.10% YoY, and the stock has declined 100% over the past five years, trading near its 52-week low of $0.50. Despite a high Price/Sales ratio of 151.49, no intrinsic value or Graham Number is calculable due to negative earnings and lack of sustainable fundamentals.
Key Strengths
Recent quarter showed a positive Q/Q EPS growth of +6.9%, indicating potential short-term improvement in earnings performance
One of the last four quarters beat earnings estimates (1/4), suggesting occasional operational improvement
Trading at a historically low price ($0.51), which may appeal to speculative investors seeking deep value
Insider activity, though bearish, is minimal (only two sales of 1 share each), suggesting limited large-scale exits
Peer comparison shows some biotech firms with similar negative metrics, indicating ADTX is not an outlier in sector-wide struggles
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness, including negative ROA, declining profitability, and poor cash flow management
Current ratio and quick ratio of 0.02 indicate severe liquidity issues and inability to meet short-term obligations
Revenue has declined 89.10% YoY, with no signs of recovery, and earnings are deeply negative and inconsistent
No analyst coverage or target price data, indicating lack of institutional interest and high uncertainty
Stock has lost 100% of its value over the past 5 years, with no technical or fundamental support for a rebound
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ADTX against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ADTX from our newsroom.
Newest → oldest
No matching news yet.